Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

AstraZeneca Launches Zegfrovy in U.S. After Accelerated FDA Approval

AstraZeneca’s U.S. launch of Zegfrovy opens a potential oncology revenue stream, but accelerated approval leaves clinical confirmation as a …

Oct 22, 2026
Pharmaceutical

AbbVie’s INTREPID Data Strengthens the Case for Dermatology Pipeline Diversification

AbbVie’s Phase 3 INTREPID results show stronger hidradenitis suppurativa responses than the comparator, adding depth beyond Humira and Skyri…

Oct 22, 2026
Pharmaceutical

Biohaven Stock Jumps as FDA Accepts Troriluzole Resubmission and Ono Deal Adds Validation

Biohaven’s $BHVN shares jumped 25% after FDA acceptance of its troriluzole resubmission, while an Ono deal added cash and external validatio…

Oct 22, 2026
Pharmaceutical

Cencora’s $2.4 Billion American Oncology Network Deal Pushes Deeper Into Cancer Care

Cencora’s $2.4 billion acquisition of American Oncology Network marks a strategic move from drug distribution into direct cancer-care provis…

Oct 21, 2026
Pharmaceutical

Unicycive Stock Gains 6.8% After FDA Accepts OLC Resubmission

Unicycive shares rose 6.8% premarket after the FDA accepted its OLC resubmission, creating a regulatory event-driven setup ahead of a formal…

Oct 21, 2026
Pharmaceutical

BioCryst’s New Orladeyo Formulation Expands Rare-Disease Growth Opportunity

FDA approval of a new Orladeyo oral pellet formulation gives BioCryst a fresh catalyst that could broaden access and extend the product’s co…

Oct 21, 2026
Pharmaceutical

Jemperli’s Accelerated FDA Approval Could Expand AnaptysBio’s Royalty Opportunity

Jemperli’s expanded FDA approval could strengthen AnaptysBio’s royalty opportunity while limiting its exposure to clinical-trial execution.

Oct 21, 2026
Pharmaceutical

Alcon’s Neurotech Acquisition Deepens Its Push Into Ophthalmic Pharmaceuticals

Alcon’s acquisition of Neurotech Pharmaceuticals could broaden its ophthalmic drug pipeline and expand its focus beyond eye-care devices.

Oct 21, 2026
Pharmaceutical

Cencora’s $2.4 Billion Oncology Acquisition Tests the Case for Vertical Integration

Cencora’s $2.4 billion American Oncology Network deal expands its role from drug distribution into oncology care delivery.

Oct 21, 2026
Pharmaceutical

Novo Nordisk’s CagriSema Delivers 25% Weight Loss in Women, Raising Stakes in the GLP-1 Market

Novo Nordisk’s CagriSema produced 25% weight loss in women in a late-stage analysis, sharpening focus on its next-generation obesity franchi…

Oct 20, 2026
Pharmaceutical

Ultragenyx Stock Plunges More Than 40% After Angelman Syndrome Drug Fails Phase III Trial

Ultragenyx shares plunged more than 40% after apazunersen failed both primary and secondary endpoints in a Phase III Angelman syndrome trial…

Oct 20, 2026
Pharmaceutical

Ultragenyx Shares Sink More Than 40% After Apazunersen Fails Phase 3 Trial

Ultragenyx shares fell more than 40% after apazunersen failed both Phase 3 endpoints, spotlighting biotech’s binary clinical risk.

Oct 20, 2026